Barclays’s Tourmaline Bio TRML Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-27,801
| Closed | -$1.33M | – | 5693 |
|
|
2025
Q3 | $1.33M | Sell |
27,801
-16,540
| -37% | -$459K | ﹤0.01% | 3195 |
|
|
2025
Q2 | $709K | Buy |
44,341
+12,546
| +39% | +$203K | ﹤0.01% | 3554 |
|
|
2025
Q1 | $484K | Sell |
31,795
-26,771
| -46% | -$429K | ﹤0.01% | 3554 |
|
|
2024
Q4 | $1.19M | Buy |
58,566
+26,733
| +84% | +$673K | ﹤0.01% | 3265 |
|
|
2024
Q3 | $818K | Buy |
31,833
+23,536
| +284% | +$393K | ﹤0.01% | 3492 |
|
|
2024
Q2 | $107K | Buy |
8,297
+5,055
| +156% | +$81.3K | ﹤0.01% | 3876 |
|
|
2024
Q1 | $74.2K | Buy |
3,242
+2,538
| +361% | +$89.5K | ﹤0.01% | 4530 |
|
|
2023
Q4 | $18.4K | Sell |
704
-1,066
| -60% | -$21.3K | ﹤0.01% | 4918 |
|
|
2023
Q3 | $49.7K | Buy |
1,770
+1,065
| +151% | +$31.2K | ﹤0.01% | 3874 |
|
|
2023
Q2 | $21.4K | Sell |
705
-1,171
| -62% | -$29.9K | ﹤0.01% | 4122 |
|
|
2023
Q1 | $35.3K | Buy |
1,876
+552
| +42% | +$9.1K | ﹤0.01% | 4528 |
|
|
2022
Q4 | $13.5K | Buy |
1,324
+521
| +65% | +$8.37K | ﹤0.01% | 4880 |
|
|
2022
Q3 | $22K | Sell |
803
-14
| -2% | -$510 | ﹤0.01% | 4032 |
|
|
2022
Q2 | $37K | Sell |
817
-341
| -29% | -$26.9K | ﹤0.01% | 4162 |
|
|
2022
Q1 | $114K | Buy |
+1,158
| New | +$108K | ﹤0.01% | 3721 |
|
Barclays's TRML Position: Q4 2025 in Review
Barclays sold out of Tourmaline Bio (TRML) in Q4 2025, closing a stake of 27,801 shares — an estimated $1.33M sold.
Barclays first reported a position in TRML in Q1 2022 and held it in 15 quarters. The position peaked at $1.33M in Q3 2025. 0 funds tracked by Wall St. Rank hold TRML as of Q4 2025.
- Barclays reported no remaining Tourmaline Bio position as of Q4 2025 after selling out during the quarter.
- Barclays sold 27,801 Tourmaline Bio shares in Q4 2025, an estimated $1.33M.
- Barclays first reported a position in Tourmaline Bio in Q1 2022 and held it in 15 quarters.
- Barclays's Tourmaline Bio position peaked at $1.33M in Q3 2025.
- 0 funds tracked by Wall St. Rank held Tourmaline Bio as of Q4 2025.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.